OR WAIT null SECS
January 03, 2024
Novel molecular glues are transforming targeted protein degradation.
UK scientists are once again able to participate in the Horizon European research programme thanks to a deal struck in 2023.
January 02, 2024
With the acquisition, AstraZeneca will gain a potential RSV and hMPV combination vaccine.
The EHDS aims to increase access to health data, but how will it impact pharma?
Clarivate has released its 2024 Drugs to Watch report, highlighting 13 therapies with great potential.
December 29, 2023
Clinician-Scientists are vital innovation spark plugs, accounting for 40% of Nobel awards in Physiology or Medicine, and two thirds of Big Pharma CSOs.
Through Syena, its oncology-focused product company, Replay will develop and manufacture T-cell receptor and natural killer cell therapies with the NIH and Miltenyi Biotec.
December 28, 2023
Is increasing molecular diversity pushing manufacturing ecosystem consolidation toward turnkey solutions?
Tome Bioscience is facilitating the transition in biology from the editing phase to the cut-and-paste phase.
December 27, 2023
The midterm report of the European Medicines Agencies Network Strategy finds that the network has strengthened and is on track to achieve its objectives.